SNTI Earnings Date: Nov 12, 2026 (Estimated) — Senti Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SNTI's next earnings date?
Senti Biosciences, Inc. (SNTI) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.21 on revenue of $15,867.
How did SNTI do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Senti Biosciences, Inc. posted EPS of -$0.41 versus the -$0.27 estimate, a miss of 46.4%. Revenue was $17,000 against a $17,000 estimate. The stock's 1-day post-earnings move was -4.2%.
How much does SNTI stock move after earnings?
SNTI beat EPS estimates in 2 of its last 6 reported quarters. Over the last 8 reports the stock moved an average of 7.8% (up or down) in the day after earnings.
About Senti Biosciences, Inc.
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.27 | -0.41 | -46.43% | $17,000 | ❌ Miss | -4.23% | -13.45% | -33.18% |
| 2026-05-14 | Q1 2026 | -0.34 | -0.14 | +58.82% | $16,000 | ✅ Beat | +8.00% | +1.77% | -0.29% |
| 2026-03-27 | Q4 2025 | -0.46 | -0.53 | -15.22% | $22,000 | ❌ Miss | -10.36% | -2.85% | +20.26% |
| 2025-11-13 | Q3 2025 | -0.58 | -0.69 | -18.97% | $0 | ❌ Miss | -10.06% | +1.12% | -32.40% |
| 2025-03-20 | Q4 2024 | -3.13 | -0.67 | +78.59% | $0 | ✅ Beat | +4.84% | -5.25% | +13.11% |
| 2024-11-14 | Q3 2024 | — | -6.31 | — | $0 | — | -7.73% | -9.01% | +119.31% |
| 2024-08-13 | Q2 2024 | — | -2.45 | — | $0 | — | +10.15% | +6.09% | +57.36% |
| 2024-03-21 | Q4 2023 | -2.30 | -4.20 | -82.61% | $0 | ❌ Miss | -6.64% | -19.77% | -40.23% |
Showing last 8 quarters.